The experience elicited by hallucinogens presents the highest similarity to dreaming within a large database of psychoactive substance reports by Sanz, Camila et al.
ORIGINAL RESEARCH
published: 22 January 2018
doi: 10.3389/fnins.2018.00007
Frontiers in Neuroscience | www.frontiersin.org 1 January 2018 | Volume 12 | Article 7
Edited by:
Rick Strassman,
University of New Mexico School of
Medicine, United States
Reviewed by:
Matthias E. Liechti,
University Hospital Basel, Switzerland
Michael Kometer,
University of Zurich, Switzerland
*Correspondence:
Enzo Tagliazucchi
tagliazucchi.enzo@googlemail.com
Specialty section:
This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Neuroscience
Received: 02 November 2017
Accepted: 04 January 2018
Published: 22 January 2018
Citation:
Sanz C, Zamberlan F, Erowid E,
Erowid F and Tagliazucchi E (2018)
The Experience Elicited by
Hallucinogens Presents the Highest
Similarity to Dreaming within a Large
Database of Psychoactive Substance
Reports. Front. Neurosci. 12:7.
doi: 10.3389/fnins.2018.00007
The Experience Elicited by
Hallucinogens Presents the Highest
Similarity to Dreaming within a Large
Database of Psychoactive Substance
Reports
Camila Sanz 1, Federico Zamberlan 1, Earth Erowid 2, Fire Erowid 2 and
Enzo Tagliazucchi 1,3*
1Departamento de Física, Universidad de Buenos Aires, Buenos Aires, Argentina, 2 Erowid Center, Grass Valley, CA,
United States, 3Brain and Spine Institute, Paris, France
Ever since the modern rediscovery of psychedelic substances by Western society,
several authors have independently proposed that their effects bear a high resemblance
to the dreams and dreamlike experiences occurring naturally during the sleep-wake
cycle. Recent studies in humans have provided neurophysiological evidence supporting
this hypothesis. However, a rigorous comparative analysis of the phenomenology (“what
it feels like” to experience these states) is currently lacking. We investigated the semantic
similarity between a large number of subjective reports of psychoactive substances and
reports of high/low lucidity dreams, and found that the highest-ranking substance in
terms of the similarity to high lucidity dreams was the serotonergic psychedelic lysergic
acid diethylamide (LSD), whereas the highest-ranking in terms of the similarity to dreams
of low lucidity were plants of the Datura genus, rich in deliriant tropane alkaloids.
Conversely, sedatives, stimulants, antipsychotics, and antidepressants comprised most
of the lowest-ranking substances. An analysis of the most frequent words in the
subjective reports of dreams and hallucinogens revealed that terms associated with
perception (“see,” “visual,” “face,” “reality,” “color”), emotion (“fear”), setting (“outside,”
“inside,” “street,” “front,” “behind”) and relatives (“mom,” “dad,” “brother,” “parent,”
“family”) were the most prevalent across both experiences. In summary, we applied
novel quantitative analyses to a large volume of empirical data to confirm the hypothesis
that, among all psychoactive substances, hallucinogen drugs elicit experiences with
the highest semantic similarity to those of dreams. Our results and the associated
methodological developments open the way to study the comparative phenomenology
of different altered states of consciousness and its relationship with non-invasive
measurements of brain physiology.
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INTRODUCTION
“The indolic alkaloids psilocybine and psilocine are the main
hallucinogenic principles of the sacred mushrooms (. . . ). The
mushrooms cause both visual and auditory hallucinations, with the
dreamlike state becoming reality” (Schultes and Hofmann, 1979).
Our everyday experience of wakefulness is only one among many
different states or modes of consciousness that are available
to us. This experience can be diminished or even disappear
during states such as deep dreamless sleep, under anesthesia,
coma or in the vegetative state (Boly and Seth, 2012; Hobson,
2017). However, other brain states are characterized by more
subtle modifications to the contents of consciousness. The most
frequent of suchmodifications appear in the form of vivid dreams
during the rapid eye movement (REM) phase of healthy human
sleep. Dreams are characterized by vivid multimodal imagery
(sometimes construed as realistic “hallucinations”), loss of the
sense of agency and volitional control, dissociation between the
first-person point of view and the bodily self of the dreamer,
suppressed metacognitive function and heightened emotional
reactivity (Hobson, 2009; Nir and Tononi, 2010). Dreams during
which the dreamer is aware of experiencing a dream instead of
wakefulness and does not identify with the “dreaming self ” but
with the everyday waking self are usually termed “lucid dreams”
(La Berge et al., 1981; Voss et al., 2009).
Conscious states sharing some of these features with dreaming
occur as a consequence of neuropsychiatric disorders (Hobson,
1999; Scarone et al., 2007), can be induced by psychoactive
substances (Kraehenmann, 2017) and in certain cases by direct
electrical stimulation of the cortex (Herbet et al., 2014). One
remarkable example of drugs1 capable of inducing experiences
with features common to dreaming is the family of serotonergic
or “classical” psychedelics. These substances have been known
and used in different parts of the world for millennia (Schultes
and Hofmann, 1979; Metzner, 1998), but it is only after the
synthesis (1938) and self-administration (1943) of lysergic acid
diethylamide (LSD) by Swiss chemist Albert Hofmann that
Western society became increasingly aware of their existence,
leading to gradual but deep changes in psychiatry, culture and
society (Hofmann, 1980). The action of serotonergic psychedelics
is based on their high affinity for serotonin 5-HT2A receptors
(Glennon et al., 1984; Vollenweider et al., 1998; Kraehenmann
et al., 2017; Preller et al., 2017) and is characterized by marked
changes in consciousness that include simple and complex visual
imagery, distortions in the sense of self and in the relationship
between the body and the environment, disinhibited emotions,
and alterations in cognition and thought processes (Schmid et al.,
2015; Nichols, 2016).
While the experience elicited by serotonergic psychedelics
has long been ascribed a dreamlike quality (Jacobs, 1978;
Schultes and Hofmann, 1979; Fischman, 1983), only recently
experiments in humans have provided evidence supporting
a relationship between these drugs and REM sleep dreams
(Carhart-Harris and Nutt, 2014; Carhart-Harris R. L. et al.,
1The terms “drug” and “substance” are here used interchangeably to refer to
psychoactive molecules and the plants and fungi containing them.
2014; Kraehenmann, 2017). This evidence comes mostly
from neuroimaging experiments using LSD and psilocybin
(the psychoactive compound behind the psychedelic effects
of Psilocybe mushrooms) (Carhart-Harris et al., 2012, 2016;
Tagliazucchi et al., 2014). Earlier studies demonstrated that LSD
facilitates REM sleep in humans when administered during
sleep or before sleep onset (Muzio et al., 1966; Torda, 1968;
Green, 1969) and that N,N-dimethyltryptamine (DMT; an
orally-inactive serotonergic psychedelic) induces spontaneous
eye movements similar to those observed during REM sleep
(Strassman, 2000).
In terms of rigorous analysis of the associated phenomenology
(the first-person perspective of “what it feels like” to have an
experience) evidence supporting a relationship between dreams
and serotonergic psychedelics is scarcer. The recent work of
Kraehenmann and colleagues established that LSD increases the
“cognitive bizarreness” of mental imagery (Kraehenmann et al.,
2017) (a characteristic quality of dream content; Hobson et al.,
1987). Other studies have asked participants to explicitly self-
assess the “dreamlike quality” of their psychedelic experience
(Studerus et al., 2011; Carhart-Harris and Nutt, 2014; Carhart-
Harris R. L. et al., 2014; Schmid et al., 2015; Dolder et al.,
2016; Carhart-Harris et al., 2016). However, a quantitative and
hypothesis-free comparison of first-person reports of psychedelic
experiences and dreaming is currently lacking.
Other hallucinogen drugs2 acting through different
pharmacological mechanisms can induce experiences that are
also characteristic of REM sleep dream mentation. Dissociative
psychedelics are chiefly synthetic anesthetic agents that disrupt
the capacity for information transmission in the brain, even
though such drugs can also be found in nature, e.g., muscimol,
present in Amanita muscaria mushrooms. Examples include
arylcyclohexamines ketamine and phencyclidine (PCP) (Morris
and Wallach, 2014). When administered in sub-anesthetic doses,
these drugs may lead to feelings of detachment from the body,
self and environment, as well as perceptual distortions and
hallucinations, depersonalization (feeling the self as unreal or
lacking agency) and derealization (feeling the environment
as unreal) (Hansen et al., 1988; Jansen, 1993; Malhotra et al.,
1996; Pomarol-Clotet et al., 2006; Wilkins et al., 2011). Some of
these experiences are frequent during normal dream episodes,
especially the dissociation between the first-person point of
view and the bodily self, while others are more characteristic
of lucid dreams (e.g., derealization) (Hobson, 2009; Nir and
Tononi, 2010; Thompson, 2014). Substances termed “deliriants”
(Duncan and Gold, 1982) include the tropane alkaloids atropine,
scopolamine, and hyoscyamine that are present in the flowering
plants of the Solanaceae family (such as those in the Brugmansia
and Datura genera) (Farnsworth, 1968; Schultes and Hofmann,
1979). The anticholinergic effect of these alkaloids leads to a
state of delirium and confusion with hallucinations and complex
visual imagery, in contrast to the relatively simple imagery
experienced under the influence of serotonergic psychedelics
(Safer and Allen, 1971; Osterholm and Camoriano, 1982; Bersani
et al., 2013). Importantly, this imagery is frequently perceived as
2We use the term “hallucinogen” to refer to deliriants and both dissociative and
serotonergic psychedelics (see Nichols, 2004).
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real and the users might not be aware that they are undergoing
a drug-induced altered state of consciousness. This feature is
common to dreams of low lucidity, during which the dreamer
lacks the metacognitive capacity to identify the experience and
its content as a dream (Kahan and LaBerge, 1994), but is absent
in the experiences elicited by dissociative and serotonergic
psychedelics (Nichols, 2016).
The phenomenological commonalities and divergences
between dreaming and the effects of dissociative psychedelics
and deliriants have received comparatively less attention than
those of serotonergic psychedelics. The neurophysiological
bases for these experiences and their relationship to those
underlying REM sleep dream episodes also remain largely
unexplored. In this work we seek to perform a comprehensive,
large-scale analysis of subjective reports of the experiences
elicited by a wide range of psychoactive substances including
hallucinogens, as well as other drugs having less direct impact
on the general quality of conscious experience (e.g., stimulants,
sedatives, antipsychotics, antidepressants). Our main objective
is to determine the semantic similarity between these reports
and those of dreams, directly addressing the hypothesis that
the experiences elicited by serotonergic psychedelics bear a
high resemblance to dreaming (Carhart-Harris and Nutt, 2014;
Carhart-Harris R. L. et al., 2014; Kraehenmann, 2017). More
generally, we extend this hypothesis to encompass dissociative
psychedelics and deliriants, and investigate whether the degree
of similarity between the associated experiences and dreaming
depends on the level of lucidity.
MATERIALS AND METHODS
Corpora Selection
Reports of psychoactive substance use were downloaded from
the “experience vaults” in www.erowid.org and are here
referred to as the “Erowid corpus.” The webpage www.erowid.
org is a “member-supported organization providing access to
reliable, non-judgmental information about psychoactive plants,
chemicals, and related issues” containing, among other resources,
a large number (>20,000) of reports associated with the
use of different psychoactive substances. Our research relied
upon Erowid’s reviewed and edited collection of experience
reports, and followed Erowid’s terms of use that require
researchers to coordinate with Erowid’s research team in order
to avoid misinterpretations of their data (https://erowid.org/
general/about/about_copyrights.shtml). We discarded reports
that resulted from the combination of different substances.When
certain reports appeared under more than one category (e.g.,
under “phenylethylamine” and “2C-B”) we classified them in the
most specific way unless such specificity dramatically reduced
the number of reports associated with each individual substance
(as in the case of psilocybin mushrooms, encompassing different
species such as Psilocybe mexicana and Psilocybe cyanescens).
We distinguished between reports of plants or fungi and their
psychoactive compounds (e.g., between mescaline and cacti such
as Lophophora williamsii and Echinopsis pachanoi). Finally, we
only included substances that contained at least 10 reports. The
names of all 165 psychoactive substances included in this study,
together with the number of associated subjective reports, their
similarity to dreams of low/high lucidity (see Figures 1, 2) and
their primary and secondary categories are listed in Table 1.
In determining the categories we adopted a hybrid criterion
based on pharmacological action and the subjective effects
induced by the substances. Serotonergic or “classical”
psychedelics (5-HT2A agonists) were grouped based on
their mechanism of action (even though their subjective effects
are generally difficult to discriminate; Wolbach et al., 1962).
The category of dissociative psychedelics comprised primarily
NMDA antagonists such as ketamine and PCP, but also included
substances with other mechanisms of action (e.g., Amanita
muscariamushrooms). The same applies to the case of deliriants,
which in most cases were Solanaceae plants rich in tropane
alkaloids. Entactogen drugs were categorized primarily by their
subjective effects [a representative drug in this category is
“ecstasy” or 3,4-methylenedioxymethamphetamine (MDMA)].
Stimulants included dopaminergic drugs such as cocaine,
amphetamines and modafinil, as well as others of different
pharmacological profile. Similarly, depressants/sedatives were
defined by their effect on the central nervous system and included
substances such as benzodiazepines as well as different natural
and synthetic opioid analgesics. Prescription antidepressants
and antipsychotics (also including plants of antidepressant
effect, such as Hypericum perforatum or St. John’s wort) were
grouped together into one category. While only two plants in the
Erowid corpus are consumed primarily for their oneirogen effect
(Calea zacatechichi and Silene undulata) we created a category
that includes them, given their relevance for the present study.
Certain substances had a large number of subjective reports
but their relatively unique mechanism of action did not justify
the creation of a new category, such substances were classified
as “other.” Examples include plants of the Cannabis genus and
cannabinoid receptor agonists, and Salvia divinorum. Finally,
all substances were given a primary and a secondary category
(even though in many cases those were identical) based on
different facets of their subjective effects (e.g., MDMA was
classified primarily as an entactogen and secondarily as an
stimulant) or the fact that their mechanism of action depends on
the combination of substances of different categories [e.g., the
psychedelic effects of ayahuasca result from the combination of
plants rich in the orally-inactive serotonergic psychedelic DMT
with beta carbolines acting as monoaminooxidase inhibitors
(MAOI) present in the liana Banisteriopsis caapi].
Dream reports were obtained from www.dreamjournal.net,
a free service with over 15,000 users and over 200,000 dream
reports. Besides the dream narratives themselves, some reports
include additional information such as the level of lucidity,
cohesion (both rated from one to five points) and whether the
dreamer had the intent of achieving lucidity. The level of lucidity
was used to separate dreams of low (1 point) and high (5 points)
lucidity. A total of 2,914,498/716,189words comprising reports of
low/high lucidity dreams were obtained for the present analysis
and comprise the “Dreamjournal corpus.”
While both www.erowid.org and www.dreamjournal.net are
curated to avoid the posting of unrelated or poor quality content,
it is impossible for the curators to assess the validity of the
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FIGURE 1 | Ranking of psychoactive substances in the Erowid corpus in terms of the similarity of their subjective reports to those of high lucidity dreams (Dreamjournal
corpus). The rectangles on the left/right zoom into the top 20 lowest/highest ranking substances and the pie charts indicate the proportion of each primary category.
Substances are represented with circles that are color-coded based on their category (the color of the center/border corresponds to the primary/secondary category).
FIGURE 2 | Ranking of psychoactive substances in the Erowid corpus in terms of the similarity of their subjective reports to those of low lucidity dreams (Dreamjournal
corpus). The rectangles on the left/right zoom into the top 20 lowest/highest ranking substances and the pie charts indicate the proportion of each primary category.
Substances are represented with circles that are color-coded based as in Figure 1.
circumstances associated with the reports (e.g., the identity of
the consumed substance or its dosage, or whether dreamers
achieved lucidity or not). This point is further discussed below
(see “Methodological Considerations and Limitations” in the
Discussion section).
Corpora Preprocessing
The preprocessing of the text corpora was performed using
the Natural Language Toolkit (NLTK, http://www.nltk.org/) in
Python 3.4.6 (Bird, 2006). Both corpora of subjective reports
were first separated into individual words after discarding all
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TABLE 1 | The 165 psychoactive substances included in the study, with the number of reports (N), their primary and secondary classification (the color-code is the same
as in Figures 1, 2, and can be found in the bottom right of the table), and the ranking of the substances in terms of their similarity to high/low lucidity dreams.
N Primary Secondary Rank (high/low) Substance N Primary Secondary Rank (high/low)
Salvia divinorum 1,267 8/19 Damiana 41 109/128
Cannabis 827 5/5 Valerian 41 123/124
MDMA 770 16/9 4-Ho-DiPT 40 77/98
LSD 718 1/2 Morphine 40 99/101
DXM 422 13/15 2C-D 40 80/100
Morning glory 334 38/34 Blue Lotus 40 113/131
2C-I 295 40/40 1P-LSD 40 21/27
Cocaine 289 89/71 DOB-DragonFLY 39 54/56
Amphetamines 250 71/50 6-APB 39 108/115
Datura 250 3/1 Ethylphenidate 38 154/153
Nutmeg 247 73/72 4-Acetoxy-DiPT 38 75/94
5-MeO-DMT 247 43/58 1,4-Butanediol 38 135/121
DMT 236 15/29 GBL 38 116/108
Metamphetamine 235 45/22 Heimia salicifolia 37 144/154
25I-NBOMe 233 46/43 Hash 37 25/18
Argyreia nervosa 224 51/42 DOB 36 14/17
Mitragyna speciosa 218 161/163 4-AcO-DET 36 83/113
2C-E 206 29/31 4-Fluoroamphetamine 35 158/152
5-MeO-DiPT 182 52/45 Acorus calamus 35 150/149
AMT 175 37/26 PCP 35 10/8
Tramadol 173 162/157 Cyclobenzaprine 33 115/116
Ketamine 164 17/25 DOI 32 72/82
2C-T-7 157 68/73 Yerba mate 32 125/117
2C-B 143 53/51 Iboga 32 33/53
Dimenhydrinate 143 12/7 Ibogaine 32 31/35
Amanita muscaria 142 35/41 AL-LAD 29 30/32
Echinopsis pachanoi 139 18/24 Hydromorphone 29 98/106
DPT 137 36/44 Oxymorphone 28 159/150
Heroine 133 74/61 A. peregrina 28 27/28
Caffeine 119 78/62 Trazadone 27 63/64
Nitrous oxide 118 34/49 Afrafinil 27 164/164
Synthetic cannabis 117 57/57 Opium 27 58/59
Zolpidem 114 26/16 MDAI 26 138/141
Oxycodone 111 117/102 Mirtazapine 25 122/127
Kava 104 95/107 Psychotria viridis 25 41/38
2C-T-2 101 69/78 Carisoprodol 25 81/75
Methoxetamine 95 39/46 Betel nut 24 93/76
Ayahuasca 93 11/20 5-HTP 24 119/122
GHB 88 106/97 Piracetam 24 124/147
Modafinil 86 134/132 Amitriptyline 23 96/79
MDPV 86 146/140 DOM 23 32/33
5-MeO-AMT’ 84 88/89 Atropa belladonna 23 19/12
Gabapentin 76 136/125 Lophophora williamsii 23 2/4
Mephedrone 74 142/136 Sertraline 23 111/83
JWH-018 73 70/66 Ephedrine 22 112/95
Mimosahuasca 72 50/48 Zopiclone 22 86/81
Tobacco 70 97/77 Piperazines 21 139/146
Brugmansia 69 6/3 4-Acetoxy-MiPT 21 55/52
Opium (poppies) 132/133 Coffee 20 76/54
(Continued)
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TABLE 1 | Continued
N Primary Secondary Rank (high/low) Substance N Primary Secondary Rank (high/low)
Calea zacatechichi 68 28/65 TFMPP 20 110/118
Methylphenidate 68 107/85 DMAE 20 137/159
Hydrocodone 64 103/90 Butylone 20 102/86
MDA 63 44/30 Banisteriopsis caapi 19 42/39
Methylone 62 94/104 Phenibut 19 160/161
Paroxetine 61 128/114 TMA-2 19 49/55
Venlafaxine 60 145/130 Lorazepam 19 22/10
Methadone 60 133/120 Olanzapine 18 151/143
2C-C 60 82/96 Diazepam 18 105/103
Fentanyl 59 120/123 Passion flower 17 149/145
Alcohol 58 84/68 Benzylpiperazine 17 114/112
Alcohol (hard) 57 59/37 Etizolam 17 163/144
Echinopsis peruviana 56 7/13 Mescaline 16 9/14
Alprazolam 55 66/36 Alcohol (beer) 16 100/91
4-AcO-DMT 55 20/23 Atomoxetine 15 141/142
Melatonin 54 60/105 Hypericum perforatum 15 152/148
Bupropion 54 104/93 MBDB 15 126/137
Codeine 54 118/111 2-Aminoindan 14 152/156
Cannabinoid agonists 53 91/99 Scopolamine 14 62/63
Buprenorphine 52 156/145 3-MeO-PCP 13 64/80
Crack 48 85/69 Propylhexedrine 13 129/126
Sceletium tortuosum 48 155/155 2C-T-4 12 92/110
A. colubrina 48 79/92 Triazolam 12 157/160
Dipt 45 67/84 Barbiturates 12 165/165
2C-P 45 56/60 IAP 12 101/88
Catnip 45 130/134 Meperidine 12 140/151
Ether 45 23/21 Ethylone 12 143/138
DOC 45 47/47 2C-T-21 12 121/129
Yohimbe 45 137/149 Silene undulata 11 48/87
Leonotis leonurus 44 148/158 Serotonergic Dissociative
5-MeO-DALT 44 87/109 Entactogen Depressant/sedative
Quetiapine 44 127/119 Stimulant Deliriant
5-MeO-MIPT 41 65/74 MAOI Antipsychotic/antidepressant
4-HO-MiPT 41 61/70 Oneirogen Other
punctuation marks (word repetitions were allowed). Each word
was lemmatized using NLTK (i.e., converted to the root from
which it is inflected). All words were converted to lowercase
and lemmatized words containing less than three characters were
discarded.
Since texts from the Erowid corpus are likely to be
influenced by the nature of the substance being reported, we
compiled a list of words including substance names, different
slang variations, and words relating to the possible routes
of administration. A total of 12,465 words fulfilling these
criteria were manually selected and the lemmatized versions
of these words were discarded from the Erowid corpus.
The rationale between this “censoring” of the corpus was
to retain words relating to the experienced effects but not
to the surrounding circumstances prior to the use of the
substances.
Latent Semantic Analysis
The basis for the present analysis is comparing the profile of
word frequencies between reports of each substance from the
Erowid corpus and dream reports of high/low lucidity from the
Dreamjournal corpus. As a first approximation, we estimated
that if the word occurrence frequencies of two texts are highly
correlated, the topics being described in those texts must be
related. Note that this analysis is not based on the frequency of
individual words, but on the relationship between all frequencies
in each pair of texts.
For a large vocabulary of terms the occurrence frequencies are
likely to be sparse, i.e., most terms will not appear in either text
and therefore their frequency will be zero. To avoid this situation
we used Latent Semantic Analysis (LSA) (Landauer, 2006), a
natural language processing technique based on the hypothesis
that words with similar meaning appear with similar frequency
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in texts (Sahlgren, 2008). Before applying LSA we computed
the frequency of the different words using the term frequency–
inverse document frequency (tf-idf) transform, as implemented
in scikit-learn (www.scikit-learn.org; Leskovec et al., 2014). The
tf-idf transform computes a matrix in which rows are unique
words in the corpus and columns represent “documents” (in
this case, each document is either a substance from the Erowid
corpus or the collection of high/low lucidity dreams from the
Dreamjournal corpus). The product of the term frequency and
the inverse document frequency determines the entries of this
matrix. The term frequency is defined as the count of times each
term appears in each document. The inverse document frequency
is defined as the logarithmically scaled inverse fraction of the
documents containing the term. To eliminate very frequent/rare
terms from the corpus, only those terms appearing in more/less
than 5%/95% of the documents were retained.
To apply LSA, the word-by-document matrix obtained using
the tf-idf transform was decomposed into the product of three
matrices using Singular Value Decomposition (SDV; Klema and
Laub, 1980). Of the three resulting matrices (U, S, V), S contains
in its diagonal the matrix of singular values ordered by size,
and U and V are real unitary matrices (their size is determined
by the number of words and documents, respectively). To
reduce the number of linearly independent rows (terms) while
preserving the similarity structure among columns (documents),
only the first D largest singular values were retained and all
others set to zero, resulting in the reduced matrix of singular
values S∗. We retained the D = 20 largest singular values (a
comparison of the results using different choices of D is shown
in Figure 8). Computing the product of U, S∗, V yields a low-
rank approximation of the word-by-document frequency matrix,
which mitigates the problem of sparseness and provides the
similarity between documents based on context-sensitive term
occurrence. For instance, even though the sentences “the garden
was full of flowering roses” and “a vase with daisies sits on the
table” share no words in common, they will be identified as
similar as they both relate to the term “flower.” Previous work has
established the adequacy of LSA to classify the subjective effects
of different psychoactive substances (Bedi et al., 2014).
Finally, after obtaining the rank-reduced version of the term
frequency matrix we computed the semantic similarity between
the subjective reports of each substance in the Erowid corpus
and the reports of high/low lucidity dreams by computing the
Pearson linear correlation coefficient between the associated
columns of the matrix.
RESULTS
In Figure 1 we show all 165 substances from the Erowid
corpus ranked according to the similarity of their associated
reports to those of high lucidity dreams. Each substance is
represented as a colored point, the center of each point is
color-coded based on the primary category of the substance
and the border is color-coded based on its secondary category.
For instance, ayahuasca is represented with a purple center and
an orange border, indicating it is a combination of a MAOI
that enables the psychedelic effects of DMT. The left (“Lowest
similarity”) and right (“Highest similarity”) panels zoom into
the top and bottom 20 substances according to the similarity
of their subjective effects to high lucidity dreaming. The pie
charts indicate the proportion of substances of each primary
category within the top and bottom 20 drugs. The highest-
ranking substance was LSD, followed by Lophophora williamsii
(peyote, a cactus containing the serotonergic psychedelic
mescaline) and then plants of the Datura genus (containing
deliriant tropane alkaloids). The highest-ranking dissociative
psychedelic was PCP. Among the top 20 substances the only
ones that were not classified as hallucinogens were plants
of the Cannabis genus whose main psychoactive effects are
mediated by tetrahydrocannabinol (a partial agonist of the
cannabinoid receptors CB1 and CB2; Kumar et al., 2001),
Salvia divinorum (a psychoactive plant capable of producing
intense alterations in consciousness mediated by salvinorin-A,
a kappa opioid receptor agonist; Roth et al., 2002) and MDMA
(a substituted amphetamine with entactogen and stimulant
effects produced by facilitation of the presynaptic release of
serotonin, norepinephrine and dopamine; Nichols, 1986). As
shown in the pie chart, hallucinogens accounted for almost 80%
of the top 20 substances. Conversely, the bottom 20 substances
included neither dissociative/serotonergic psychedelics nor
deliriants, and consisted mostly of depressant/sedatives such
as babiturates, benzodiazepines/benzodiazepine analogs
(etizolam, triazolam) and opioids (tramadol, oxymorphone),
stimulants (adrafinil, ethylphenidate, 2-Aminoindane) and
antidepressant/antipsychotics (Hypericum perforatum and
olanzapine).
Figure 2 shows the same information as Figure 1 but for the
similarity to low lucidity dreams. The top ranked substances
included a larger proportion of deliriants. Plants of the Datura
and Brugmansia genera ranked first and third, respectively.
Dimenhydrinate (a medication used to treat motion sickness that
is recreationally abused due to its deliriant properties at high
doses; Halpert et al., 2002) was among the top ranked substances,
while it was absent for the similarity to high lucidity dreams
(Figure 1).
It is interesting to note that melatonin, Silene undulata
and Calea zacatechichi were the three substances with the
highest difference in their similarity between high and low
lucidity dreaming. The latter two are plants traditionally
employed as oneirogens and purported to increase dream lucidity
(Schultes and Hofmann, 1979), whereas melatonin is a hormone
endogenous to the human body that has been explored as a
lucidity-enhancing agent (La Berge, 2003). Conversely, the three
drugs that resulted in less “lucid” experiences (according to the
comparison of their associated reports with those of high vs. low
lucidity dreams) were alprazolam, sertraline, and clonazepam.
The first and third of these drugs are benzodiazepines, while
sertraline is an antidepressant of the selective serotonin reuptake
inhibitor class.
Figure 3A shows the average rank of all substances divided
by category and by the similarity of their reports to those
of high/low lucidity dreams (the categories corresponding
to MAOI, oneirogens and others were excluded due to
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FIGURE 3 | (A) Average substance rank (per category) in terms of the similarity of the reported effects to high/low lucidity dream reports (median ± 25th and 75th
percentiles, “+” represents outliers). Higher numbers correspond to higher similarity (the highest possible rank is 165). The categories “oneirogen,” “MAOI,” and
“other” were excluded from this figure due to their small sample size (n ≤ 6). The drug category presented a significant effect on the similarity with dream reports
(F = 31.34, p < 0.0001, multi-factor ANOVA), while the interaction between dream lucidity and similarity with dream reports was non-significant (F = 0.02, p = 0.88).
(B) Post-hoc Wilcoxon signed-rank tests for the difference in the similarity to dreams for each pair of drug categories. Black squares represent significant differences
(p < 0.05) for the pair of drug categories in the corresponding rows and columns.
their small number of substances). The top three categories
were dissociative psychedelics, serotonergic psychedelics and
deliriants, followed by entactogens, depressant/sedatives,
antipsychotic/antidepressants and stimulants. A multi-factor
analysis of variance (ANOVA) was conducted with the ranking of
the drugs as dependent variable and two grouping variables (drug
category and dream lucidity). A significant effect of drug category
on the similarity to dreams was observed (F= 31.34, p< 0.0001),
while the interaction between dream lucidity and similarity with
dream reports was non-significant (F = 0.02, p = 0.88).
Afterwards we conducted post-hoc Wilcoxon signed-rank tests
for the difference in the similarity to dreams for each pair of
drug categories (Figure 3B). We observed significant differences
between all hallucinogen drugs and depressants/sedatives,
antipsychotic/antidepressants and stimulants. No significant
differences were found among hallucinogens or among the
group of depressants/sedatives, antipsychotic/antidepressants
and stimulants. Entactogen reports were significantly less similar
to dream reports for some hallucinogen drugs, which depended
on the level of dream lucidity.
Figure 4A shows that it is possible to predict the semantic
similarity between reports of different substances based on their
semantic similarity to dreams of high lucidity. Four high-ranking
substances belonging to different categories (LSD, plants of the
Datura genus, PCP and MDMA) were selected. Each point in
the scatter plots represents a substance in the Erowid corpus
(color-coded as in Figures 1, 2) with its X axis coordinates
indicating the similarity of its subjective reports to those of
each of the four selected substances and its Y axis coordinates
to reports of high lucidity dreams. The correlation coefficient
between both similarity indices (Spearman correlation,ρ) is
shown as an inset [LSD (ρ = 0.89), Datura genus (ρ = 0.87),
PCP (ρ = 0.83), MDMA (ρ = 0.72)]. Figure 4B shows the same
information for four substances that rank lower in terms of their
similarity to high lucidity dream reports: barbiturates, cocaine,
venlafaxine and Calea zacatechichi. In contrast to the scatter
plots shown in Figure 4A it is clear that a lower correlation
exists between both similarity indices [Barbiturates (ρ =−0.47),
Cocaine (ρ = 0.11), Venlafaxine (ρ = −0.45), Calea zacatechichi
(ρ = 0.44)]. Figure 5 shows the same information as Figure 4
but for the similarity to low lucidity dreams [LSD (ρ = 0.86),
Datura genus (ρ = 0.91), PCP (ρ = 0.87), MDMA (ρ = 0.74),
Barbiturates (ρ = −0.40), Cocaine (ρ = 0.11), Venlafaxine
(ρ =−0.33), Calea zacatechichi (ρ = 0.27)].
After establishing that subjective reports of hallucinogens
present the highest semantic similarity to dream reports, we
investigated the most frequent terms within dreams of high and
low lucidity, and for the selection of substances presented in
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FIGURE 4 | Prediction of the similarity between the subjective report of substances and dreaming experiences of high lucidity, based on the similarity to LSD, plants of
the Datura genus, PCP and MDMA (A) and to reports of barbiturates, cocaine, venlafaxine and Calea zacatechichi (B). Substances are represented with circles that
are color-coded as in Figure 1. The inset shows the value of the Spearman’s rank correlation coefficient (ρ).
FIGURE 5 | Prediction of the similarity between the subjective report of substances and dreaming experiences of low lucidity, based on the similarity to LSD, plants of
the Datura genus, PCP and MDMA (A) and to reports of barbiturates, cocaine, venlafaxine and Calea zacatechichi (B). Substances are represented with circles that
are color-coded as in Figure 1. The inset shows the value of the Spearman’s rank correlation coefficient (ρ).
Figures 4A, 5A. Figure 6 shows a word cloud representation of
the frequency of the most 40 common terms in the vocabulary
of high (left panel) and low (right panel) lucidity dream reports
(all word clouds were generated using www.wordart.com). The
most common terms in both cases related to the setting/location
(the term “setting” itself, as well as others such as “door,”
“street,” “outside,” “wall,” “behind”), emotions (“fear,” “peaceful,”
“happiness,” “confusion,” “anxiety”), relatives (“mom,” “dad,”
“brother”) and perception (“see,” “face,” “movement”). The main
difference between both sets of reports related to the frequency
of the term “lucid” itself, which possibly reflected the fact that
Dreamjournal users explicitly commented on their intents of
achieving lucid dreaming.
We produced similar word clouds for the reports of
substances with high (LSD, plants of the Datura genus, PCP
and MDMA) and low (barbiturates, cocaine, venlafaxine and
Calea zacatechichi) similarity to dream reports (Figure 7A).
Consistent with the effects of these substances, high-frequency
terms in reports of hallucinogens related to distortions in visual
perception, emotions, and the setting of the experiences. The
term “hallucination” did not appear among the most frequent
for LSD reports, consistent with the fact that serotonergic
psychedelics are characterized by relatively simple visual imagery.
MDMA reports also included terms that relate to the typical
setting of entactogen use (e.g., “club,” “boyfriend,” “alone,”
“conversation,” “person”). Substances with reports of low
similarity to dreaming included terms that did not relate to
perception/setting/consciousness/emotion but depended on the
substance, its effect and the general circumstances of its most
common recreational use. For instance, barbiturate reports
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FIGURE 6 | Word clouds for the top 40 most frequent terms in dream reports of high (left) and low (right) lucidity.
included frequent terms related to their effects and their intended
medical use (“relaxed,” “insomnia,” “prescribe”), as well as to their
addictive potential (“tolerance,” “sober,” clean”). Similar terms
appeared for cocaine, another substance with addictive potential
(“addict,” “quit,” “craving”). Frequent terms related to Calea
zacatechichi vaguely indicated its use as an oneirogen (“lucid,”
“vivid,” “visuals”), but seemed to relate mostly to the preparation
of the substance and recommendations for other Erowid readers
(“recommend,” “bowl,” “boil,” “ounce,” “material,” “mix,” “store,”
“fill,” “add”).
We computed the rank of each term in the vocabulary (in
terms of its frequency in the rank-reduced tf-idf matrix) for
reports of LSD, plants of the Datura genus, PCP and MDMA, as
well as for reports of high/low lucidity dreaming. We averaged
both ranks and produced a word cloud in which term size is
weighted by the average rank, i.e., terms that rank high both
in substance and dream reports appear with the largest sizes.
These word clouds are shown in Figure 7B. The most prevalent
terms related to facets of the experience that were both relevant
for hallucinogens and dreams. These included terms associated
with perception (“see,” “visual,” “face,” “reality,” “color”), emotion
(“fear”), setting (“outside,” “inside,” “street,” “front,” “behind”)
and relatives (“mom,” “dad,” “brother,” “parent,” “family”).
The results shown in the previous figures are based on
retaining the components associated with the 20 largest singular
values (D = 20) after performing SVD. To investigate the
parametric dependence of the results upon the number of
retained singular values, we repeated all analyses using D = 20,
25, 30, 35, 40, 45, 50, 55, 60, 65, and 70. We then computed
the Spearman correlation coefficient between the substance
rankings obtained for each pair of number of singular values. The
resulting correlation matrices are shown in Figure 8 for dreams
of low lucidity (left) and high lucidity (right). While the highest
correlation coefficients appeared close to the diagonal (indicating
that the ranking of the substances changed continuously with the
relative difference of the number of retained singular values), all
correlation coefficients were larger than 0.995, meaning that the
substance rankings were highly stable for the different choices of
this parameter.
DISCUSSION
We have applied techniques from natural language processing
to a large corpus of subjective reports to investigate the
hypothesis that, among a wide range of psychoactive substances,
hallucinogens lead to experiences that are most similar to
those reported during dreaming. Anecdotal and historical
evidence -supported by neurophysiological observations- led to
the formulation of the aforementioned hypothesis by different
authors (Jacobs, 1978; Schultes and Hofmann, 1979; Fischman,
1983; Carhart-Harris and Nutt, 2014; Carhart-Harris R. L. et al.,
2014; Kraehenmann, 2017). We support it for the first time with
phenomenological evidence based on subjects freely reporting
the nature of their experiences. In the following we discuss
dreaming and drug-induced alterations in consciousness for
three separate domains: changes in sensory perception, self-
awareness, and metacognitive function. We also discuss the
consistency of our results with our current phenomenological
and neurophysiological understanding of dreaming, and their
contribution toward a better characterization of dreaming and
drug-induced altered states of consciousness.
Changes in Sensory Perception
Dreams and certain psychoactive substances can bring about
changes in perception, predominantly visual but also auditory,
tactile and proprioceptive (Hobson, 2009; Nir and Tononi, 2010;
Thompson, 2014; Nichols, 2016). Dreams occurring during
REM sleep frequently involve complex and vivid imagery that
may not be recognized as a departure from ordinary conscious
wakefulness. Dreams are highly visual experiences, full of rich
imagery comprising colored and moving objects identical
or similar to those frequently perceived during wakefulness
Frontiers in Neuroscience | www.frontiersin.org 10 January 2018 | Volume 12 | Article 7
Sanz et al. Hallucinogen Drugs and Dreaming
FIGURE 7 | Word clouds for the top 40 most frequent terms in the reports of four substances with high similarity to dream reports (LSD, plants of the Datura genus,
PCP and MDMA) and in the reports of four substances with lower similarity to dream reports (barbiturates, venlafaxine, cocaine, and Calea zacatechichi) (A). (B)
shows word clouds based on the average ranking of each term in the reports of the four psychoactive substances of (A) and in the reports of high/low lucidity dreams.
(Hobson, 1988). While it has been argued that visual imagery
during REM sleep can be characterized as a hallucination
(i.e., as bottom-up perception Hobson, 1992a), Thompson,
Nir and Tononi have eloquently defended the position that its
phenomenology is closer to that of spontaneous imagination (i.e.,
top-down perceptual imagery Nir and Tononi, 2010; Thompson,
2014).
In contrast, serotonergic psychedelics tend to produce subtler
perceptual modifications that cannot be easily classified in
either category and that are frequently described as “simple”
visual imagery (Nichols, 2004, 2016) [however, some exceptional
serotonergic psychedelics such as N,N-diisopropyltryptamine
(DiPT) primarily induce auditory distortions; Shulgin and
Carter, 1979]. The nature of simple visual imagery elicited by
serotonergic psychedelics is consistent with their effect at cortical
areas early in the visual hierarchy (Ermentrout and Cowan,
1979; Bressloff et al., 2002; de Araujo et al., 2012; Carhart-
Harris et al., 2016; Kometer and Vollenweider, 2016; Roseman
et al., 2016). In addition, changes in higher visual areas have
been reported for the acute effects of serotonergic psychedelics.
For instance, psilocybin increased glucose metabolism in the
temporal lobe, which might indicate altered processing of visual
information along the ventral stream (Vollenweider et al.,
1997). Psilocybin also modified relatively late evoked potentials
associated with simple and complex visual imagery (Kometer
et al., 2011, 2013). We can speculate that the complexity of
visual imagery depends on both the dosage and the nature of
the drug. For instance, relatively high doses may increase the
dreamlike character of visual imagery, and certain serotonergic
psychedelics (such as DMT) are prone to produce stronger
and interactive complex imagery, especially with eyes closed
(Strassman et al., 1994; Strassman, 2000; Shanon, 2002; Luke,
2011). Since it is difficult to obtain reliable information on dosage
from the Erowid corpus (see the “Methodological Considerations
and Limitations” section), the relationship between psychedelic-
induced complex visual imagery and dream mentation should
be investigated in the future using more controlled experimental
paradigms.
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FIGURE 8 | Pairwise correlation matrices between the rank of the substances in terms of their similarity to dreams of low (left) and high (lucidity), computed after
retaining different numbers of singular values.
The most frequent visual modifications induced by
serotonergic psychedelics are elementary in nature and
include color and pattern recognition enhancement (Hartman
and Hollister, 1963; Oster, 1966), the presence of trails behind
moving objects (Dubois and VanRullen, 2011), drifting of the
visual field, and imagery that is predominantly geometric in
nature (Klüver, 1942; Siegel and Jarvik, 1975; Kometer and
Vollenweider, 2016; Roseman et al., 2016). This last feature of
perceptual distortions has been explained by the form of the
retino–cortical map and the architecture of the human primary
visual cortex (Ermentrout and Cowan, 1979; Bressloff et al., 2002;
Kometer and Vollenweider, 2016). These observations suggest
that visual distortions elicited by typical recreational doses of
serotonergic psychedelics and REM sleep dreams might differ
in terms of their complexity and similarity to the visual content
typical of conscious wakefulness. In spite of these differences,
a close relationship between visual imagery during sleep and
the serotonin system is suggested by the observation that
serotonergic antidepressants alleviate the presence of complex
visual hallucinations in patients with narcolepsy, a neurological
disorder leading to the abnormal occurrence of REM sleep
episodes (Manford and Andermann, 1998).
The differences in the nature of visual imagery elicited by
serotonergic psychedelics and dreaming are manifest in the word
clouds shown in Figure 7A. In the example of LSD, the most
frequent terms are related to visual perception and to the act of
seeing/perceiving itself (“see,” “visual,” “vision”), to simple visual
imagery (“color,” “pattern”) and to more complex concepts that
could either be the content of complex visual imagery or part of
the setting (“face,” “door”). This is consistent with experimental
studies showing that LSD produced more elementary compared
to complex hallucinations (Carhart-Harris et al., 2016; Kometer
and Vollenweider, 2016; Liechti et al., 2017). High-frequency
terms related to simple visual imagery were absent in the reports
from plants of the Datura genus, PCP and MDMA. When
ranking terms based on their joint frequency in LSD and dream
reports (Figure 7B) terms related to simple visual imagery lost
prominence.
Dissociative psychedelics are not known to produce strong
perceptual modifications at low doses; however, higher
dosage can lead to a state of perceptual dissociation from
the environment that is characterized by intense and complex
visual hallucinations (Muetzelfeldt et al., 2008). In the case of
ketamine, such state is colloquially referred to as “k-hole” and
also results in alterations in self-awareness and the relationship
between the body boundaries and the environment (to be
discussed below). Deliriant plants rich in tropane alkaloids such
as those of the Datura and Brugmansia genera produce complex
visual hallucinations that are convincing to the user. In certain
cases, the user might even interact with such hallucinations
and completely lose awareness of undergoing a sensory
disconnection with the environment (Safer and Allen, 1971;
Osterholm and Camoriano, 1982; Bersani et al., 2013; Schmid
et al., 2015). Thus, these substances might generate visual
content highly similar to that experienced during dreaming.
It must be noted, however, that the incapacity to identify the
hallucinatory character of visual content is not a requisite for
experiencing vivid and complex imagery. For instance, such
imagery is experienced during dreams of high lucidity, even
though dreamers are aware of the nature of their experience.
Pharmacologically, realistic eyes-closed visual imagery (referred
to as “brain movies” by Shulgin; Shulgin and Shulgin, 1995)
can be induced by substituted amphetamines of entactogen
effect such as 3-methoxy-4,5-methylenedioxyamphetamine
(MMDA), even though the user easily identifies such content as
artificial.
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Psychoactive substances belonging to the other categories
included in this study are not primarily characterized as
hallucinogenic and do not routinely induce perceptual
modifications. Certain stimulants such as metamphetamine can
occasionally induce confusional states that include multimodal
hallucinations, but these states are not among the sought-
after effects of the drugs and tend to be exceptions (McKetin
et al., 2006). Other substances such as alcohol, barbiturates
and benzodiazepines are known for their capacity to induce
withdrawal syndromes including features common to the
experiences elicited by deliriant alkaloids, such as confusion,
delusions and convincing multimodal hallucinations (Sellers,
1988; Schuckit, 2014). Again, these states do not represent
normal recreational use and are not likely to inflate the similarity
between the subjective reports of these substances and those of
dreams. Thus, our knowledge of how substances of different
categories impact on sensory perception is consistent with the
semantic similarity between subjective reports of hallucinogens
and dreams, with the caveat that deliriants could generate visual
hallucinations closer to those experienced during dreams than
those elicited by serotonergic psychedelics.
Serotonergic Psychedelics, Dreams, and
Cortical Inhibition
While the neurophysiological underpinnings of drug-induced
simple and complex visual imagery remain to be completely
understood, recent neuroimaging experiments suggest that they
relate to enhanced coupling between primary visual areas
and higher cortical regions and to increased thalamocortical
functional connectivity (Carhart-Harris et al., 2016; Müller et al.,
2017). Such changes are likely mediated by the activation of
serotonin 5-HT2A receptors, as activation of 5-HT2A receptors
has been identified as the key mechanism of action of
serotonergic hallucinogens (Glennon et al., 1984; Vollenweider
et al., 1998; Rickli et al., 2016; Kraehenmann et al., 2017; Preller
et al., 2017). These receptors are highly expressed in posterior
brain regions linked to visual information processing (Saulin
et al., 2012), causing an increase in the excitability of layer V
cortical pyramidal neurons projecting to inhibitory interneurons
(Andrade and Weber, 2010; Bastos et al., 2012). The highly
visual nature of psychedelic experiences and REM sleep dreams
is supported by increased occipital metabolism and cerebral
blood flow during both states (Braun et al., 1997, 1998; Carhart-
Harris et al., 2016)—but a recent report showed decreased
occipital blood flow under psilocybin, which could be related to
dose, effects specific to this drug, or to differences in the data
acquisition method (Lewis et al., 2017). These variables aside,
solid experimental evidence supports the fact that serotonergic
psychedelics alter the metabolism and activation levels of the
occipital lobe. An inverse correlation between the intensity of
the experienced visual imagery and the spectral power of cortical
oscillations in the alpha (8–12Hz) band suggests that visual
imagery induced by LSD could relate to a loss of top-down
inhibition of ongoing spontaneous activity (Carhart-Harris et al.,
2016), given that alpha oscillations have been implicated in the
suppression of such activity (Klimesch et al., 2007; Jensen and
Mazaheri, 2010). In agreement with these findings on LSD-
induced visual imagery, previous studies have also linked alpha
suppression to the formation of visual imagery induced by other
serotonergic psychedelics such as psilocybin (Kometer et al.,
2013) or ayahuasca (Valle et al., 2016). The fact that alpha
oscillations inhibit large-range functional connectivity as inferred
from functional magnetic resonance recordings (Tagliazucchi
et al., 2012; Chang et al., 2013) supports the internal consistency
of the multimodal results reported by Carhart-Harris et al.
(2016).
More generally, serotonergic psychedelics appear to elicit their
effects by disrupting inhibitory processes in the brain (Guilbaud
et al., 1973; Haigler and Aghajanian, 1973; Vollenweider et al.,
1997; Kometer et al., 2013; Carhart-Harris R. et al., 2014;
Nichols, 2016; Schmidt et al., 2017). The serotonergic psychedelic
psilocybin has been shown to reduce brain metabolism in the
posterior cingulate cortex (PCC), a key hub in the default mode
network (DMN) of the brain that could exert an inhibitory
influence in other brain regions (Carhart-Harris et al., 2012).
It has been hypothesized that the dreamlike quality of the
experience elicited by psilocybin relates to increased activity in
the medial temporal lobe (MTL) as a result of decreased PCC-
mediated inhibition (Carhart-Harris and Nutt, 2014; Carhart-
Harris R. et al., 2014). This hypothesis is consistent with
neuroimaging studies showing that MTL activity increases after
psilocybin infusion (Tagliazucchi et al., 2014) and that such
activity increases are correlated to the subjective assessment of
the dreamlike quality of the experience (Carhart-Harris andNutt,
2014). MTL activity is also enhanced in humans during REM
sleep (Maquet et al., 1996; Miyauchi et al., 2009) and pathological
increases inMTL activity due to temporal lobe epilepsy can result
in an altered state of consciousness that is ascribed a dreamlike
quality by the patients (Gloor et al., 1982). Suppressed PCC
activity also is a landmark feature of human REM sleep (Maquet
et al., 1996; Braun et al., 1997), suggesting that loss of PCC-
mediated inhibition also underlies altered consciousness during
dreaming. Furthermore, the direct electrical stimulation of the
PCC has been shown to induce a state that is both similar to
the serotonergic psychedelic experience and dreaming (Herbet
et al., 2014). This study provides evidence of a causal relationship
between disruption of PCC-mediated cortical inhibition and
the dreamlike quality of the subjective experience. Further
causal evidence is provided by the observation that dreamlike
experiences can be elicited by direct electrical stimulation of
the MTL (Halgren et al., 1978). Thus, we propose that altered
consciousness during the psychedelic experience and dreaming
might relate to disrupted PCC and MTL activity, providing a
common neurophysiological basis for their phenomenological
similarity.
Less is known about the relationship between the changes
in brain activity due to dissociative psychedelics and dreaming.
These substances act by inhibiting the propagation of brain
activity, either by decreasing excitation (e.g., ketamine,
an NMDA antagonist; Tyler et al., 2017) or increasing
inhibition (e.g., muscimol, a selective GABAA agonist present
in Amanita muscaria mushrooms; Frølund et al., 2002).
As in the case of serotonergic psychedelics, the analysis of
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magnetoencephalography recordings acquired after the infusion
of a sub-anesthetic dose of ketamine show widespread decreases
in alpha power. Whether a mechanistic explanation for these
changes can be found in the loss of PCC-mediated cortical
inhibition remains to be investigated (Muthukumaraswamy
et al., 2015).
From a pharmacological perspective, the similarity between
dreaming and the effects of deliriant substances is paradoxical,
since tropane alkaloids act by blocking the neurotransmitter
acetylcholine (i.e., they are anticholinergic agents; Safer and
Allen, 1971), whereas dreaming is associated with higher levels of
acetylcholine (Hobson, 1992b). The acute deliriant effects of the
tropane alkaloids contained in plants such as those in the Datura
and Brugmansia genera are difficult to investigate in humans
using neuroimaging tools, and whether their effects depend on
the disruption of cortical inhibition remains unknown. However,
electroencephalography and magnetoencephalography studies of
scopolamine do not show the drop in alpha power that is typical
of serotonergic psychedelics and ketamine (Ebert and Kirch,
1998; Osipova et al., 2003), suggesting a different mechanistic
explanation for its acute effects.
Changes in Self-awareness
During ordinary wakeful consciousness the first-person point
of view is intertwined with the bodily location: the self is
located within a body recognized as its own, with well-
defined boundaries and a sense of agency over its actions and
movements. This perspective can be deeply modified during
dreaming and by the effect of psychoactive substances. While
frequently the point of view of the dreamer is consistent with
a first-person perspective, the dreamer often sees herself and
her actions from a third-person perspective (Thompson, 2014).
This divergence is also typical after high doses of dissociative
psychedelics such as ketamine and PCP (Muetzelfeldt et al.,
2008; Wilkins et al., 2011; Morris and Wallach, 2014) and is
one of the defining characteristics of out-of-body experiences,
i.e., experiences involving the feeling of leaving one’s body or
perceiving it from the outside (autoscopy) (Blanke et al., 2002,
2004; Blanke and Arzy, 2005; Bünning and Blanke, 2005).
The phenomenology of dreaming also includes the experience
of “boundlessness” during which the self is either grown
to encompass its surroundings or “dissolves” into them
(Windt, 2010). This experience is frequently referred to as
“oceanic boundlessness” or “ego-dissolution” (Millière, 2017).
Serotonergic psychedelics have long been known to induce ego
dissolution experiences, which have been sometimes ascribed a
spiritual or mystical character (Strassman, 2000; Griffiths et al.,
2006). As Albert Hofmann recalls from his first LSD experience:
“Ego and the outer world are separated in the normal condition
of consciousness, in everyday reality; one stands face-to-face
with the outer world; it has become an object. In the LSD
state the boundaries between the experiencing self and the outer
world more or less disappear, depending on the depth of the
inebriation” (Hofmann, 1980). As recently reviewed by Millière,
7% of Erowid subjective reports of psilocybe mushrooms,
LSD, Salvia divinorum, DMT, 5-MeO- DMT, ayahuasca and
ketamine describe an ego-dissolution experience (Millière, 2017).
A higher incidence (≈50%) of ego-dissolution experiences
has been reported in large-scale studies using questionnaires
(Griffiths et al., 2006; Studerus et al., 2011); this discrepancy
is likely related to the use of questionnaires vs. freely reported
narratives. Consistent with these observations, ego-dissolution
is also reported when LSD and psilocybin are administered
experimentally (Lebedev et al., 2015; Carhart-Harris et al., 2016;
Tagliazucchi et al., 2016; Liechti et al., 2017).
These observations suggest that changes in self-awareness,
related either to the dissociation between the first-person point
of view and the bodily self or to the loss of boundaries
between the bodily self and the environment, are factors
driving the semantic similarity between subjective reports of
hallucinogens and dreaming. Also, the prevalence of words
representing persons closely related to the narrator (“mom,”
“dad,” “brother,” “parent,” “family”) could indicate altered self-
referential processing during dreams and under the influence
of hallucinogens. Whether both experiences share common
neurophysiological bases is to be determined by future
experiments. The neural mechanisms of drug-induced ego-
dissolution have received more attention than their REM sleep
counterparts, presumably due to the difficulty of performing
neuroimaging experiments during sleep in combination with
the necessity of adopting a serial awakening paradigm to probe
the occurrence of distortions in self-awareness. A recent study
has shown that LSD-induced ego-dissolution relates to increased
global connectivity of fronto-parietal and insular regions,
especially those located within the temporo-parietal junction
(Tagliazucchi et al., 2016). These results are consistent with the
proposition that out-of-body experiences and other alterations
in self-awareness stem from a failure to integrate multisensory
information at the temporo-parietal junction (Blanke and
Arzy, 2005). Future studies should investigate whether this
proposition also holds for disturbed self-awareness during REM
sleep.
While hallucinations are occasionally reported for drugs
chemically unrelated to dissociative/serotonergic psychedelics
and deliriants, alterations in self-awareness (including but
not limited to those mentioned in the previous paragraphs)
seem to be specific to these substances and to the kappa
opioid receptor agonist Salvia divinorum (Millière, 2017). This
plant contains salvinorin-A, a kappa opioid receptor agonist
capable of producing potent hallucinogenic effects (Roth et al.,
2002). These effects include derealization, depersonalization
and detachment from the self and the environment, in
combination with intense simple and complex visual imagery,
and alterations in auditory and vestibular input (Sumnall
et al., 2011; MacLean et al., 2013; Addy et al., 2015). Thus,
the effects of Salvia divinorum include certain features of
serotonergic psychedelics (i.e., the nature of the visual imagery),
dissociative psychedelics (depersonalization and derealization)
and anticholinergic deliriants (impaired awareness of undergoing
a drug-induced experience). These observations are consistent
with the high similarity between Salvia divinorum reports
and dreams (Figures 1, 2), and suggest further experimental
work to elucidate the physiological underpinnings of this
similarity.
Frontiers in Neuroscience | www.frontiersin.org 14 January 2018 | Volume 12 | Article 7
Sanz et al. Hallucinogen Drugs and Dreaming
Changes in Metacognition and Dream
Lucidity
As we know from our everyday experience, during most dreams
the dreamer is not aware of experiencing a dream and lacks
voluntary control over her actions. This lack of awareness occurs
in spite of events that would stand out as incongruent, bizarre or
outright impossible during wakefulness (Nir and Tononi, 2010).
The suppression of the capacity to recognize the abnormal nature
of such events could be linked to diminished metacognitive
function during REM sleep, i.e., the diminished ability of the
dreamer to reflect upon and understand her own thought
processes (Kahan and LaBerge, 1994). This suppression of insight
and self-reflection is consistent with the deactivation of two
regions involved in metacognition: the dorsolateral prefrontal
cortex (DLPFC) and the frontopolar cortex (Maquet et al., 1996;
Braun et al., 1997). Correlational evidence links these brain
regions to metacognition (Fleming and Dolan, 2014) and their
magnetic stimulation is known to impair metacognitive function
(Rounis et al., 2010; Ryals et al., 2015). Conversely, it has
been speculated that lucidity relates to preserved metacognitive
capacity during REM sleep dreams (Kahan and LaBerge, 1994).
A recent study provided support for this claim by showing
that lucid dreamers have greater gray matter volume in the
frontopolar cortex as well as higher activation in a thought-
monitoring task, both relative to a control group of non-lucid
dreamers (Filevich et al., 2015).
As in REM sleep episodes, serotonergic psychedelics decrease
the oscillatory activity and functional connectivity of the
DLPFC (Muthukumaraswamy et al., 2013). In contrast to
non-lucid dreamers, the users remain aware of the nature
of their experience and can situate themselves within an
altered state different from normal wakefulness. However,
both states of consciousness are characterized by increased
cognitive bizarreness of mental imagery (Kraehenmann et al.,
2017). Cognitive bizarreness can be defined as the presence of
improbable, impossible or incongruent events during a given
experience, and has been shown to be a reliable indicator
of dreamlike mentation (Hobson et al., 1987). Furthermore,
Kraehenmann et al. have shown that LSD-induced increases
in cognitive bizarreness correlate with other aspects of the
psychedelic experience such as loss of self-boundaries and
cognitive control, and are mediated by serotonin 5-HT2A
receptor activation (Kraehenmann et al., 2017). An important
difference between the psychedelic state and non-lucid dreams
is that only in the latter the disruption of metacognitive function
limits the capacity for reflecting upon the cognitive bizarreness
of the experience and determining the departure from ordinary
wakefulness, which is possibly related to hypofrontality during
sleep (Dietrich, 2003).
Deliriants are known to induce a confusional state during
which the user can lose awareness of experiencing drug-induced
alterations in consciousness. It is interesting to note that a
larger proportion of deliriant substances ranked among the
most similar to dream reports of low lucidity in comparison to
dreams of high lucidity. In the first case the top three ranking
substances included two deliriant agents (plants of the Datura
and Brugmansia genera) while in the second case they included
only one (Daturas). We must note, however, that no significant
differences were found when comparing their similarity to
dreams of high vs. low lucidity (Figure 3). Thus, further study
is required to assess whether the preservation of metacognitive
function during lucid dreams decreases the phenomenological
similarity to deliriant-induced alterations in consciousness.
A category of substances highly relevant to the present
discussion is that of oneirogens. The Erowid corpus contains
reports of two plants primarily classified as oneirogens: Calea
zacatechichi and Silene undulata (Schultes and Hofmann, 1979).
Calea zacatechichi is a flowering plant native to Mexico and
Central America that is consumed, among other uses, for its
capacity to induce vivid dreams. It is believed that certain
sesquiterpenes underlie its oneirogen effects (Herz and Kumar,
1980). Silene undulata, also known as Silene capensis or African
dream root, is a plant native to South Africa traditionally
employed by the Xhosa people to facilitate vivid and lucid dreams
(Sobiecki, 2008). While it might be surprising that the subjective
reports of these two plants do not rank higher in terms of their
similarity to dreaming, the word cloud for Calea zacatechichi
(Figure 7) indicates that the most frequent terms were related
to recommendations, expectations, and the required preparation
process of the plant. However, it is interesting to note that
the subjective reports associated with Calea zacatechichi and
Silene undulata increased their ranking more than any other
substance when compared to dreams of high lucidity vs. dreams
of low lucidity. This might relate to the capacity of these plants
to restore metacognitive function during sleep, a possibility
requiring further scientific investigation.
Methodological Considerations and
Limitations
We propose that the application of tools for semantic analysis
such as LSA to large corpora of subjective experiences could
open the way to the development of a quantitative “comparative
phenomenology” allowing to determine the phenomenological
similarity between altered states of consciousness and to relate
such similarity to the underlying neurophysiological mechanisms
(Varela, 1996). While understanding the phenomenological
subtleties of different experiences requires careful introspection
and reporting (Thompson and Zahavi, 2007), the “ecological”
approach of analyzing freely written subjective reports is likely
sufficient to determine the degree of similarity between altered
states of consciousness. Ample literature ascribing dreamlike
qualities to certain hallucinogenic substances, together with the
availability of large and curated corpora of subjective reports,
made the present analysis a natural first choice to apply this
methodology. Future analyses should address the hypothesis that
certain spontaneously occurring altered states of consciousness
(such as near death experiences) are induced by psychedelic
compounds endogenous to the human brain (Strassman, 2000).
The large number of subjective reports available from online
databases such as Erowid and Dreamjournal are one of the main
strengths of our study, but also represent a source of limitations.
Even though both databases are curated, there is no certainty that
the substances consumed by Erowid users are chemically pure
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and that their identity is what the users claim in their reports.
Also, Erowid reports frequently lack information on the dosage
and, when present, it is not possible to corroborate whether
such information is accurate. A placebo-controlled study could
alleviate expectation issues in the subjective reports; however, it is
unlikely that such study could include a large number of different
substances and reports. It is also not possible to determine
whether Dreamjournal reports are based on REM sleep episodes
or on dreamlike imagery occurring at other times of the sleep
cycle, such as hypnagogic or hypnopompic imagery consisting of
hallucinatory content that lacks the elaborate narratives of REM
sleep dreaming (Hobson et al., 2000). To compensate for the
possibility of missing or erroneous information, these databases
provide a very large number of reports from which a meaningful
signal is likely to emerge in spite of uncontrolled sources of noise
(Halevy et al., 2009).
Conclusions
In summary, we have developed a method to determine the
similarity between altered states of consciousness based on large
corpora of subjective reports and applied it to corroborate the
hypothesis that the experiences elicited by certain drugs bear
a high resemblance to dreaming. While this hypothesis chiefly
concerned serotonergic psychedelics, we found that dissociative
psychedelics and deliriants led to reports of experiences more
similar to those of dreams. We speculate that this higher
similarity could be based on the nature of the distortions
in perception and self-awareness elicited by these substances,
combined with the impairment of metacognitive function in
the case of deliriants. Future studies should focus on these
phenomenological features and on establishing a link with the
underlying neurophysiological mechanisms.
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